NCT05424549View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

May 9, 2022

Study Completion Date

May 9, 2022

Conditions
Dry Eye Syndromes
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution dosed six times over two consecutive days

Trial Locations (1)

L4W 1A4

Cliantha Research, Mississauga

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY

NCT05424549 - A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease | Biotech Hunter | Biotech Hunter